PRESS RELEASES

Date Title and Summary View
Toggle Summary Galectin Therapeutics Reports 2017 Financial Results and Provides Business Update
NORCROSS, Ga. , March 29, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for the year ended December 31, 2017 . These results are included in the Company's Annual Report on Form
View HTML
Toggle Summary Galectin Therapeutics to Present at Two International Conferences in March
NORCROSS, Ga. , March 09, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber , M.D., the Company’s CEO and CMO, will participate in two upcoming international  conferences in
View HTML
Toggle Summary Galectin Therapeutics to Present at 2nd Annual H.C. Wainwright NASH Investor Conference
NORCROSS, Ga. , March 08, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold Shlevin , the Company’s Chief Operating Officer, will present at the 2 nd Annual H.C.
View HTML
Toggle Summary Galectin Therapeutics Announces Record Date and Annual Stockholders Meeting Date for 2018
NORCROSS, Ga. , March 05, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced March 26, 2018 is the record date for the 2018 Annual Meeting of Stockholders to be held on May 22, 2018 in Atlanta, GA.
View HTML
Toggle Summary Galectin Therapeutics to Present at 30th Annual ROTH Conference
NORCROSS, Ga. , Feb. 28, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber , M.D., the Company’s CEO and CMO, will present at the 30th Annual ROTH Conference on March 12, 2018
View HTML
Toggle Summary Galectin Therapeutics to Present at BIO CEO & Investor Conference
NORCROSS, Ga. , Feb. 06, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber , M.D., the Company’s CEO and CMO, will present at BIO CEO & Investor Conference on Tuesday,
View HTML
Toggle Summary Galectin Therapeutics Granted Patents in China and Japan that Support NASH and Cancer Immunotherapy Clinical Development Programs
The broad protection of these patents opens doors to partnerships in the world’s second- and third-largest pharmaceutical markets NORCROSS, Ga. , Jan. 25, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics , Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to
View HTML
Toggle Summary Galectin Therapeutics Announces $10 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Into 2019
NORCROSS, Ga. , Dec. 19, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced it entered into a $10 million unsecured line of credit facility with stockholder and new director Richard E. Uihlein .
View HTML
Toggle Summary Galectin Therapeutics Provides Corporate Update at Annual Meeting
Dr. Peter Traber , CEO and CMO, reviews results of NASH-CX trial that demonstrated statistically significant and clinically meaningful effects in patients who had NASH cirrhosis but did not have esophageal varices Approximately 50% of all patients with NASH cirrhosis do not have esophageal varices
View HTML
Toggle Summary Galectin Therapeutics to Webcast Corporate Update at Annual Meeting of Shareholders
NORCROSS, Ga. , Dec. 11, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that the Company will present a corporate update via live webcast immediately following the business portion of its 2017
View HTML